ClinicalTrials.Veeva

Menu

An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)

Roche logo

Roche

Status

Completed

Conditions

Anemia

Study type

Observational

Funder types

Industry

Identifiers

NCT02042833
ML25557

Details and patient eligibility

About

This observational study will evaluate patients' perception of treatment with erythropoiesis-stimulating agents in patients with chronic kidney disease not on dialysis. Eligible patients initiated on treatment with Mircera (methoxy polyethylene glycol-epoetin beta) will be followed for 6 months.

Enrollment

815 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Patients with chronic kidney disease not on dialysis (with or without previous renal transplantation)
  • Treated or not with ESA at time of visit
  • Patients for whom the treating physician had decided to initiate Mircera for medical reasons before the commencement of the study
  • Initiation of treatment with Mircera at the inclusion visit
  • Accepting and able of completing the ESA preference questionnaire

Exclusion criteria

  • Participation in a clinical trial on anemia
  • Treatment with Mircera during the 3 months before inclusion
  • Dialysis planned in the next 6 months

Trial design

815 participants in 1 patient group

Cohort

Trial contacts and locations

110

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems